Evaluation of Rare and Complex Tumours of the Thoraco-Abdominal and Soft Tissue District
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Mar 7, 2025
Trial Information
Current as of May 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on studying rare and complex tumors, specifically those found in the thoraco-abdominal area and soft tissues. The main goal is to collect detailed information about how these tumors are diagnosed, treated, and followed up over time. The study will look back at patient data from January 1, 2000, to September 28, 2017, and will also collect new information from September 29, 2017, to December 31, 2025.
If you or a family member has been diagnosed with a rare or complex malignant tumor and can provide informed consent, you may be eligible to participate in this study. There are no specific exclusions, meaning anyone fitting the criteria can join. Participants can expect to share their medical history and treatment details, which will help researchers better understand these rare conditions and improve future care. This study is currently recruiting participants, and all genders aged 65 and older are welcome to join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with histologic diagnosis of rare or highly complex malignant neoplasm
- • informed consent
- Exclusion Criteria:
- • none
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, Bo, Italy
Bologna, Bo, Italy
Patients applied
Trial Officials
Maria A Pantaleo, MD
Principal Investigator
Oncology Unit, IRCCS AOUBO
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported